Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The eastern cooperative oncology group (ECOG) results

Taxol was administered as a 24-hour continuous infusion at 250 mg/m(2) in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT.